Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

MERCK & CO., INC.

(MRK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/26/2020 10/27/2020 10/28/2020 10/29/2020 10/30/2020 Date
78.84(c) 77.99(c) 76.18(c) 75.89(c) 75.21(c) Last
8 704 988 11 680 721 8 578 153 8 887 664 10 563 577 Volume
-1.24% -1.08% -2.32% -0.38% -0.90% Change
More quotes
Financials (USD)
Sales 2020 48 111 M - -
Net income 2020 12 115 M - -
Net Debt 2020 17 081 M - -
P/E ratio 2020 16,0x
Yield 2020 3,20%
Sales 2021 51 659 M - -
Net income 2021 14 050 M - -
Net Debt 2021 13 488 M - -
P/E ratio 2021 13,5x
Yield 2021 3,45%
Capitalization 192 B 192 B -
EV / Sales 2020 4,34x
EV / Sales 2021 3,98x
Nbr of Employees 71 000
Free-Float 70,6%
More Financials
Company
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or... 
Sector
Pharmaceuticals
Calendar
10/30Presentation
More about the company
Notations Surperformance© of Merck & Co., Inc.
Trading Rating : Investor Rating :
More Ratings
All news about MERCK & CO., INC.
10:45aSANOFI : to evaluate the safety and efficacy of novel investigational candidate ..
AQ
10/28MERCK : Announces Third-Quarter 2020 Financial Results
AQ
10/28MERCK : Phil Deploys 76 Community Health Mobilizers in Montserrado
AQ
10/27GLOBAL MARKETS LIVE : Focus is on Microsoft
10/27MERCK : Strong sales of drugs, vaccines, propel Merck in 3Q
AQ
10/27MERCK : 3Q20 Merck Other Financial Disclosures
PU
10/27MERCK : 3Q20 Merck Earnings Presentation
PU
10/27MERCK : Raises 2020 Adjusted EPS Guidance, Narrows Revenue Outlook, Lowers EPS G..
DJ
10/27MERCK : Strong sales of drugs, vaccines, propel Merck in 3Q
AQ
10/27MERCK : 3Q Profit Rises; Minimal Pandemic Disruption to Production, Distribution
DJ
10/27MERCK : 3Q Earnings Snapshot
AQ
10/27MERCK & CO., INC. : Results of Operations and Financial Condition, Financial Sta..
AQ
10/27MERCK : Announces Third-Quarter 2020 Financial Results
BU
10/23MERCK : Why Merck Is Playing Catch-Up in the Coronavirus -2-
DJ
10/23Why Merck Is Playing Catch-Up in the Coronavirus Vaccine Chase
DJ
More news
News in other languages on MERCK & CO., INC.
10/27En attendant un vaccin Covid-19, les labos US soutenus par leurs blockbusters
10/27Les valeurs à suivre aujourd'hui à Wall Street Mardi 27 octobre 2020
10/27MERCK & CO : dépasse les attentes
10/27Berenberg belässt Merck & Co auf 'Hold' - Ziel 88 Dollar
10/27Le bénéfice de Merck dopé par les ventes de l'anti-cancéreux Keytruda
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Stock Trading Strategies
MERCK & CO., INC - 03/26
Good timing to go long again
BUY
More Stock Trading Analysis
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Average target price 96,15 $
Last Close Price 75,21 $
Spread / Highest target 42,3%
Spread / Average Target 27,8%
Spread / Lowest Target 13,0%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.-17.31%191 944
JOHNSON & JOHNSON-5.95%361 159
ROCHE HOLDING AG-6.40%274 461
PFIZER INC.-9.95%196 047
NOVARTIS AG-22.62%176 518
NOVO NORDISK A/S9.93%154 639